IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial
Most Cited Paper
in Dialysis and Renal Disease Management
18 Months Post-Publication
Class of 2026
“IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/dialysis-and-renal-disease-management/2026/
Topics
Clazakizumab · IL-6 inhibition · Clazakizumab · Dialysis · High-sensitivity C-reactive protein · phase 2b dose-finding study · geometric mean ratio primary endpoint · serum fibrinogen reduction · serum amyloid A · secretory phospholipase A2 · lipoprotein(a) · serum albumin increase · cardiovascular risk in dialysis patients · inflammatory biomarkers · dose-ranging (2.5 mg, 5 mg, 10 mg) · thrombocytopenia safety monitoring · neutropenia safety monitoring · serious infection risk · diabetes and cardiovascular comorbidity in dialysis population · NCT05485961
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Dialysis and Renal Disease Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/dialysis-and-renal-disease-management/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459